Drug Search Results
More Filters [+]

Trotabresib

Alternative Names: trotabresib, cc-90010, cc90010, cc 90010
Latest Update: 2024-10-07
Latest Update Note: Clinical Trial Update

Product Description

Trotabresib is an orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/118021883)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trotabresib

Countries in Clinic: Canada, Japan, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: B-Cell Marginal Zone Lymphoma|Basal Cell Carcinoma|Brain Cancer|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Large Cell Carcinoma|Lymphoma|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03936465

P1

Completed

Lymphoma|Brain Cancer

2024-03-16

JapicCTI-205272

P1

Active

B-Cell Marginal Zone Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Large Cell Carcinoma|Basal Cell Carcinoma

2022-12-31

Recent News Events